文献速递肾移植肾血管病与高血压

残粒胆固醇与肾移植受者心血管事件及全因死亡的前瞻性关联:FAVORIT研究

Remnant cholesterol is prospectively associated with cardiovascular disease events and all-cause mortality in kidney transplant recipients: the FAVORIT study.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

FAVORIT试验纳入3812例肾移植受者,按基线非空腹残粒胆固醇四分位分组,中位随访4.0年。最高四分位较最低四分位心血管疾病风险显著增加(HR 1.32,95%CI 1.04-1.67),全因死亡风险亦增加(HR 1.34,95%CI 1.01-1.69),移植失败风险无显著增加(HR 1.20,95%CI 0.87-1.64)。

要点

  • 肾移植受者残粒胆固醇最高四分位心血管风险增加32%。
  • 残粒胆固醇最高四分位全因死亡风险增加34%。
  • 残粒胆固醇与移植失败风险无显著关联。

核心结论

  • 在长期肾移植受者中,残粒胆固醇与心血管疾病事件及全因死亡相关。
  • 作者认为可能有必要在肾移植受者中开展评估降残粒胆固醇治疗对上述结局影响的随机对照临床试验。

研究设计与样本

  • FAVORIT试验的事后前瞻性队列分析,纳入3812例肾移植受者,排除98例基线残粒胆固醇或协变量缺失者。
  • 基线非空腹残粒胆固醇根据血脂谱计算,按四分位分组,采用Cox比例风险回归评估与结局的关联。

主要发现

  • 中位随访4.0年,记录548例心血管疾病事件、343例移植失败和452例全因死亡。
  • 最高四分位与最低四分位相比,心血管疾病风险显著增加(HR 1.32,95%CI 1.04-1.67)。
  • 最高四分位与最低四分位相比,全因死亡风险显著增加(HR 1.34,95%CI 1.01-1.69)。
  • 最高四分位与最低四分位相比,移植失败风险无显著增加(HR 1.20,95%CI 0.87-1.64)。

临床怎么用

  • 在肾移植受者随访中,可关注残粒胆固醇水平以辅助心血管风险分层。
  • 目前尚无证据支持降残粒胆固醇治疗可改善肾移植受者结局,需等待随机对照试验验证。

局限性

  • 本研究为观察性分析,无法确立残粒胆固醇与结局的因果关系。
  • 残粒胆固醇基于非空腹血脂谱计算,可能受饮食状态影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cholesterol content of circulating triglyceride-rich lipoproteins is characterized as remnant cholesterol, although little is known about its role in the development of cardiovascular disease (CVD) outcomes, all-cause mortality or transplant failure in kidney transplant recipients (KTRs). Our primary aim was to investigate the prospective association of remnant cholesterol and the risk of CVD events in renal transplant recipients with secondary aims evaluating remnant cholesterol and renal graft failure and all-cause mortality among participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial. METHODS: Among 4110 enrolled participants, 98 were excluded for missing baseline remnant cholesterol levels and covariates. Nonfasting remnant cholesterol levels were calculated based on the lipid profiles in 3812 FAVORIT trial participants at randomization. A Wilcoxon-type test for trend was used to compare baseline characteristics across remnant cholesterol quartiles. Cox proportional hazards regression was used to evaluate the association of baseline remnant cholesterol levels with time to primary and secondary study outcomes. RESULTS: During a median follow-up of 4.0 years we documented 548 CVD incident events, 343 transplant failures and 452 all-cause deaths. When comparing the highest quartile (quartile 4) to quartile 1, proportional hazard modeling revealed a significant increase in CVD risk {hazard ratio [HR] 1.32 [95% confidence interval (CI) 1.04-1.67]} and all-cause mortality risk [HR 1.34 (95% CI 1.01-1.69)]. A nonsignificant increase in transplant failure was seen as well [HR 1.20 (95% CI 0.87-1.64)]. CONCLUSIONS: Remnant cholesterol is associated with CVD and all-cause mortality in long-term KTRs. A randomized controlled clinical trial in KTRs that assesses the potential impact of remnant cholesterol-lowering therapy on these outcomes may be warranted.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Horace RW, Roberts M, Shireman TI, et al. Remnant cholesterol is prospectively associated with cardiovascular disease events and all-cause mortality in kidney transplant recipients: the FAVORIT study. Nephrol Dial Transplant. 2022. PMID: 33760035. doi:10.1093/ndt/gfab068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。